Purpose: To report a case of successful medical treatment with oral posaconazole in refractory fungal keratitis caused by Paecilomyces lilacinus.
T he ubiquitous saprophytic filamentous fungus Paecilomyces lilacinus is a rare cause of fungal keratitis and endophthalmitis, and it occurs more commonly in patients with predisposing factors such as contact lens wear. 1 Paecilomyces keratitis can be devastating because of its poor response to conventional antifungal therapy, often requiring therapeutic penetrating keratoplasty (PKP). [1] [2] [3] [4] In this study, we describe a case of successful treatment of refractory keratitis caused by P. lilacinus using oral posaconazole, a relatively new, generally well-tolerated, and highly potent triazole.
CASE REPORT
A 57-year-old man presented with irritation, pain, photophobia, and reduced vision in the right eye. He had worn soft contact lenses for 5 years, but practiced poor lens hygiene. At presentation, his uncorrected visual acuity was 20/100 in the right eye and 20/15 corrected in the left eye. Slit-lamp examination demonstrated a 5.8 · 6.3 mm central corneal epithelial defect, a peripheral 1.5 · 2.0 mm infiltrate at the 1-o'clock position adjacent to the limbus, and stromal edema. After obtaining corneal cultures, fortified vancomycin and tobramycin were started, with application of bacitracin-polymyxin ointment at night. The infiltrate worsened. Nine days after initial presentation, cultures showed fungal growth. In vivo confocal microscopy (IVCM) (Heidelberg Retina Tomograph 3/Rostock Cornea Module; Heidelberg Engineering, Heidelberg, Germany) showed presumed hyphae at a depth of 500 mm, supporting the diagnosis of fungal keratitis ( Fig. 1A) . B-scan showed no endophthalmitis. Oral voriconazole 200 mg twice daily, as well as hourly topical amphotericin and natamycin were started; topical vancomycin and tobramycin were stopped. Nineteen days after initial presentation, the fungus was identified as P. lilacinus, and topical voriconazole 1% was added. However, the epithelial defect and infiltrate (2.5 · 2.5 mm) further worsened ( Figs. 2A, B ), and the visual acuity decreased to counting fingers.
By 22 days after presentation, a hypopyon developed, and the patient underwent therapeutic penetrating keratoplasty (PKP). Intracameral and subconjunctival injections of voriconazole (50 mg/ 0.1 mL) were given. Fungal stains and cultures of the aqueous and the removed cornea were negative, but histopathology demonstrated deep fungal elements in the corneal stroma ( Fig. 3 ). Postoperatively, topical cyclosporine 2%, voriconazole 1%, and amphotericin B were prescribed 4 times daily, and oral voriconazole was continued. Despite the continuation of antifungal therapy, increased anterior chamber inflammation, keratic precipitates, and hypopyon were noted at 11 days postoperatively, with no obvious stromal infiltration. The presence of filamentous structures in the posterior stroma resembling those seen before the PKP by IVCM ( Fig. 1B) , together with the treatment response, and improvement in inflammation were highly suggestive of recurrence. An intracameral injection of miconazole (25 mg/0.1 mL) was given, and topical miconazole was started. The infectious disease unit was consulted the same day, and the patient was placed on oral posaconazole 400 mg twice daily. After 1 week of oral posaconazole treatment, he reported significant improvement in symptoms with an increase in the uncorrected visual acuity from counting fingers at 2 feet to 20/200 and resolving inflammation. A second intracameral injection of miconazole was given. Antifungal susceptibility testing on the initial isolate, performed by a reference laboratory, returned showing high minimum inhibitory concentrations (MICs) for natamycin (.32 mg/mL at 48 hours), suggesting resistance. Susceptibility results for amphotericin were 2 mg/mL at 24 hours but .16 mg/mL, at 48 hours, whereas MICs for voriconazole (0.25 at 24 hours, 0.5 at 48 hours) and miconazole (4 at 24 and 48 hours) seemed to be favorable. Topical amphotericin was rapidly tapered off; topical miconazole and voriconazole were continued for 3 more months. Six weeks after starting posaconazole, IVCM revealed no evidence of inflammation or fungal elements (Fig. 1C ). During 5 months of posaconazole treatment, the cornea remained clear centrally (Figs. 2C, D) , and the patient achieved a best-corrected visual acuity of 20/20 after cessation of antifungal therapy. Unfortunately, the patient developed acute graft rejection 2 months later and required a keratoprosthesis type I. There was no evidence of infection at surgery, and 3.5 years after keratoprosthesis placement, the patient remains free of infection and with vision of 20/60. 
DISCUSSION
To the best of our knowledge, this is the first case report to describe successful treatment of P. lilacinus keratitis with oral posaconazole. The patient in our study, who was refractory to other topical, oral, and intracameral antifungal medications, and presented with recurrent fungal keratitis after therapeutic corneal transplantation, showed significant improvement in symptoms and signs by 1 week after treatment with posaconazole and intracameral miconazole, with no evidence of fungal elements in IVCM after 6 weeks of treatment. Furthermore, no recurrence developed during the 3.5 years of follow-up.
Risk factors for Paecilomyces keratitis include contact lens wear, as in the case of our patient, as well as ocular trauma, ocular surgery, steroid therapy, and intraocular lens implantation. 1, [5] [6] [7] Clinically, although Paecilomyces keratitis has been previously described to characteristically involve the posterior stroma with an intact epithelium, 2,4,8 our patient had a large epithelial defect. Because the clinical features are not pathognomonic for fungal keratitis, cultures are required to detect specific species.
Particularly in cases where cultures are still pending or are inconclusive, IVCM has been recently described as an adjunct tool to locate fungal elements, and has the potential to visualize them in the deep stroma. 9 Although our patient received close follow-up with serial IVCM, filamentous structures were observed until 43 days after posaconazole was started, despite clinically significant improvement.
Successful medical treatment of Paecilomyces keratitis with other antifungal agents such as voriconazole has been reported. 1, [5] [6] [7] However, there was no improvement in our patient with voriconazole, suggesting that refractory cases exist and that alternative therapies, such as posaconazole, should be considered.
Posaconazole is a triazole antifungal agent and is usually well tolerated. 8 Its efficacy on P. lilacinus has been recently shown in a murine infection model. 10 In addition, it has been recently used in a case with refractory keratitis due to Beauveria bassiana, as reported by Tu and Park. 11 Furthermore, Sponsel et al 12 successfully treated a case of Fusarium keratitis, where posaconazole was used both orally and topically. However, the commercial preparation of posaconazole that is available now is an oral suspension and should not be used topically because it contains various additives, including dyes.
Although our patient did not report any adverse effects during posaconazole therapy, the most common adverse effects are gastrointestinal symptoms, such as nausea and vomiting, as well as fever and headaches. 8 In addition, liver function tests should be monitored regularly. Tu and Park 11 reported that posaconazole had to be discontinued after 1 month of therapy because of development of elevated liver function tests and pleural effusion. 11 A limitation of this case report is the concurrent treatment with intracameral and topical miconazole. Antifungal susceptibility testing showed low MICs for both voriconazole and miconazole. Nevertheless, there was no improvement on initial voriconazole therapy, although its MIC was lower than that for miconazole. In addition, topical drops alone are unlikely to be effective in deep stromal lesions. Moreover, after intracameral miconazole, filamentous hyphae were still observed by IVCM, and thus it is very unlikely that miconazole resulted in eradication of the fungus. Nevertheless, an additional therapeutic effect of miconazole or any of the other antifungal drugs cannot be completely excluded.
In summary, this case report indicates that oral posaconazole may serve as an effective treatment for refractory Paecilomyces keratitis that is resistant to conventional therapy.
